Formation Bio

Formation Bio (formerly TrialSpark) is an AI-driven biotech and clinical trial platform company, not a venture capital fund. The formation.bio website confirms an operating business that has historically focused on running clinical trials more efficiently and developing pharmaceutical assets using technology and data infrastructure. The Crunchbase profile lists Formation Bio as a recipient of substantial venture capital funding rather than a fund itself; any investment activity from Formation Bio would be strategic corporate development for assets aligned to their drug development pipeline rather than financial venture investing. For healthcare AI founders, this is the wrong door if you are seeking a financial check. The right framing for engaging Formation Bio is as a potential customer, partner, or asset acquirer, not as an investor. Founders building AI tools for clinical trial design, patient recruitment, real-world evidence generation, or drug discovery automation could pitch Formation Bio as a customer or partnership target, and a small number of those conversations may evolve into strategic investments. Plausible strategic investment check sizes, if any, would be small and tied to commercial agreements. Founders building anything outside the drug development and clinical trial workflow should not approach Formation Bio at all; the strategic interests are tightly scoped. Entry path is LinkedIn outreach to Formation Bio business development or partnership leads, or through pharmaceutical industry networks where Formation Bio operates. Treat this as a commercial relationship-first conversation, not a venture pitch. Reallocate venture pitch time to actual VC firms and use Formation Bio as a partner-and-customer development target instead.